In our study, we used a panel of cancer cell lines with diverse p53 backgrounds, including p53-null (SKOV3, ARP-1), wild-type p53 (HepG2, HCT116), and mutant p53 (RPMI-8226, MDA-MB-231). Here, TP53 is linked to cancer.